Researchers have developed COMPASS, a breakthrough AI model that predicts immunotherapy response across multiple cancer types using tumor gene expression data. Published in Nature Medicine, COMPASS could help oncologists identify which patients benefit most from checkpoint inhibitors—avoiding unnecessary toxicities and enabling faster treatment optimization. Read the evidence-based analysis. medicine
Read the full article on GMJ Newsroom →
Was this article helpful?

